8-K: Myriad Genetics Reports Strong Q2 2024 Results, Raises Full-Year Guidance

Myriad Genetics announced a 15% year-over-year revenue increase in the second quarter of 2024, driven by strong performance across its portfolio, and raised its full-year financial guidance.

Summary

• Myriad Genetics reported a 15% year-over-year revenue growth in the second quarter of 2024, reaching $212 million.
• The company's revenue growth was primarily driven by Prenatal (25%), Pharmacogenomics (22%), and Hereditary Cancer (19%) testing.
• GAAP earnings per share improved to $(0.41) from $(1.42) in Q2 2023, while adjusted earnings per share improved to $0.05 from $(0.08).
• Myriad Genetics increased its full-year 2024 revenue guidance to a range of $835 $845 million, representing an annual growth rate of 11% to 12%.
• The company also raised its adjusted earnings per share (EPS) guidance to a range of $0.08 $0.12 for the full year.
• Test volumes increased by 9% year-over-year, reaching 389,000 in the second quarter of 2024.
• Gross margin improved to 69.6%, a 110 basis point increase year-over-year, reflecting operating leverage and improved average revenue per test.
• Adjusted operating expenses were $140.8 million, a 6% increase year-over-year, driven by investments in technology, product development, and R&D.
• The company's adjusted operating income was $7.4 million, a $14.2 million improvement year-over-year.
• Myriad Genetics also increased its long-term revenue growth target to 12%.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to strong revenue growth, improved profitability, and increased financial guidance. The company's strategic initiatives and collaborations also contribute to the positive outlook. However, some challenges in the tumor profiling segment and the overall net loss temper the sentiment slightly.

Positives

• Myriad Genetics experienced strong revenue growth across multiple product categories.
• The company demonstrated improved profitability with increased earnings per share.
• The increase in full-year guidance indicates management's confidence in future performance.
• The company is seeing market share gains in prenatal testing.
• Myriad Genetics is improving access and ease of use for customers through EMR integrations and its Labs of the Future initiative.
• The company is growing profitably and delivering improved financial results.
• Myriad Genetics is investing in innovation to reach more patients with precision medicine.
• The company's gross margin improved due to operating leverage and improved average revenue per test.
• Adjusted operating expenses as a percentage of revenue decreased year-over-year.
• Myriad Genetics has secured new patents and collaborations to advance its MRD assay.

Negatives

• Tumor profiling revenue decreased by 9% year-over-year, reflecting challenges in the biopharma environment and international business.
• The company reported a GAAP operating loss of $36.5 million for the quarter.
• The company is still experiencing a net loss of $(36.7) million for the quarter.
• The company is still experiencing a net loss of $(62.7) million for the six months ended June 30, 2024.

Risks

• The company faces risks related to potential declines in sales and profit margins of existing tests.
• There is a risk that the company may not be able to operate its business on a profitable basis.
• The company's ability to achieve revenue growth targets and generate sufficient revenue from new tests is uncertain.
• Changes in governmental or private insurer coverage and reimbursement levels could impact the company's revenue.
• Increased competition and the development of new competing tests pose a risk to the company's market position.
• The company may face challenges in developing and commercializing new tests in a timely manner.
• There are risks related to delays or problems with operating the company's laboratory testing facilities.
• Public concern over genetic testing could negatively impact the company's business.
• The company faces risks related to regulatory requirements and enforcement in the United States and foreign countries.
• The company's ability to secure additional financing, if needed, is not guaranteed.
• The company faces risks related to security breaches, loss of data, and cyberattacks.
• The company may not be able to keep pace with rapid technology changes in its industry.
• The company may be unable to comply with financial operating covenants under its credit agreements.
• The company faces risks related to current and future investigations, claims, or lawsuits.

Future Outlook

Myriad Genetics expects trends in financial performance to continue through the year and into 2025, anticipates additional market share gains in prenatal testing, and plans to continue publishing clinical validation studies and launching new products. The company also expects to improve access and ease of use for customers through EMR integrations and its Labs of the Future initiative.

Management Comments

• Paul J. Diaz, President and CEO of Myriad Genetics, stated that the company is proud to have delivered another quarter of strong double-digit year-over-year revenue growth.
• He also mentioned that the company's year-to-date 2024 revenue growth of 13% year-over-year, following 11% year-over-year growth in 2023, demonstrates the sustainability of their organic growth.
• He expressed confidence in raising the long-term revenue growth target to 12%.

Industry Context

Myriad Genetics' focus on genetic testing and precision medicine aligns with the broader industry trend towards personalized healthcare. The company's growth in prenatal testing and pharmacogenomics reflects increasing demand for these services. The collaborations with GSK and QIAGEN highlight the importance of partnerships in expanding access to diagnostic testing and advancing personalized medicine.

Comparison to Industry Standards

• Myriad Genetics' 15% year-over-year revenue growth in Q2 2024 is strong compared to some of its peers in the genetic testing industry, although specific competitor results would be needed for a more detailed comparison.
• Companies like Exact Sciences (EXAS) and Invitae (NVTA) also operate in the genetic testing space, and their growth rates and profitability metrics would be relevant benchmarks.
• The 25% growth in prenatal testing revenue suggests Myriad is gaining market share in this competitive segment, potentially outperforming some competitors.
• The company's focus on improving average revenue per test and expanding payer coverage is a common strategy in the industry to drive profitability.
• The collaboration with Personalis on MRD testing is similar to other partnerships in the industry aimed at advancing cancer diagnostics.

Stakeholder Impact

• Shareholders will likely react positively to the strong financial results and increased guidance.
• Employees may benefit from the company's growth and investments in innovation.
• Customers will benefit from improved access and ease of use of the company's products.
• Healthcare providers will have access to more advanced genetic testing options.
• Patients will benefit from the company's mission to reach more people with life-saving precision medicine.

Next Steps

• Myriad Genetics will continue to focus on growing its core product categories, including prenatal, pharmacogenomics, and hereditary cancer testing.
• The company will continue to publish additional clinical validation studies and launch new products.
• Myriad Genetics will continue to improve access and ease of use for customers through EMR integrations and its Labs of the Future initiative.
• The company will continue to invest in innovation to reach more patients with precision medicine.
• Myriad Genetics will continue to pursue collaborations and partnerships to expand its market reach and product offerings.

Key Dates

Keywords

genetic testing, precision medicine, prenatal testing, pharmacogenomics, hereditary cancer, tumor profiling, revenue growth, earnings per share, financial guidance, market share, MRD, GeneSight, MyRisk, HRD